The transcription factor fos: A janus-type regulator in health and disease

Histology and Histopathology

Volumn 24, Issue 11, 2009, Pages 1451-1461

  Durchdewald, Moritz ^a   Angel, Peter ^a   Hess, Jochen ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

Author keywords

AP 1; Bone; Cancer; CNS; Oncogene

Indexed keywords

ANIMALIA; MUS;

PROTEIN C FOS;

ANIMAL; HUMAN; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-FOS;

EID: 73349090951     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Acquaviva C., Bossis G., Ferrara P., Brockly F., Jariel-Encontre I. and Piechaczyk M. (2002). Multiple degradation pathways for Fos family proteins. Ann. NY Acad. Sci. 973, 426-434.
2. Aikawa Y., Morimoto K., Yamamoto T., Chaki H., Hashiramoto A., Narita H., Hirono S. and Shiozawa S. (2008). Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat. Biotechnol. 26, 817-823.
3. Angel P. and Karin M. (1991). The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072, 129-157.
4. Aoyagi K., Shima I., Wang M., Hu Y., Garcia F.U. and Stearns M.E. (1998). Specific transcription factors prognostic for prostate cancer progression. Clin. Cancer Res. 4, 2153-2160.
5. Bamberger A.M., Milde-Langosch K., Rossing E., Goemann C. and Loning T. (2001). Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J. Cancer. Res. Clin. Oncol. 127, 545-550.
6. Baranes D. and Razin E. (1991). Protein kinase C regulates proliferation of mast cells and the expression of the mRNAs of fos and jun protooncogenes during activation by IgE-Ag or calcium ionophore A23187. Blood 78, 2354-2364.
7. Basbous J., Chalbos D., Hipskind R., Jariel-Encontre I. and Piechaczyk M. (2007). Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol. Cell Biol. 27, 3936-3950.
8. Basbous J., Jariel-Encontre I., Gomard T., Bossis G. and Piechaczyk M. (2008). Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer? Biochimie 90, 296-305.
9. Behrens A., Jochum W., Sibilia M. and Wagner E.F. (2000). Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 19, 2657-2663.
10. Bierbaum H., Baumann S., Herr I., Tuckermann J.P., Hess J., Schorpp-Kistner M. and Angel P. (2003). Early activation and induction of apoptosis in T cells is independent of c-Fos. Ann. NY Acad. Sci. 1010, 225-231.
11. Bossis G., Ferrara P., Acquaviva C., Jariel-Encontre I. and Piechaczyk M. (2003). c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo. Mol. Cell Biol. 23, 7425-7436.
12. Bossis G., Malnou C.E., Farras R., Andermarcher E., Hipskind R., Rodriguez M., Schmidt D., Muller S., Jariel-Encontre I. and Piechaczyk M. (2005). Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol. Cell Biol. 25, 6964-6979.
13. Cahill M.A., Janknecht R. and Nordheim A. (1996). Signalling pathways: jack of all cascades. Curr. Biol. 6, 16-19.
14. Chalmers C.J., Gilley R., March H.N., Balmanno K. and Cook S.J. (2007). The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1. Cell Signal. 19, 695-704.
15. Curran T., MacConnell W.P., van Straaten F. and Verma I.M. (1983). Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells. Mol. Cell Biol. 3, 914-921.
16. David J.P., Mehic D., Bakiri L., Schilling A.F., Mandic V., Priemel M., Idarraga M.H., Reschke M.O., Hoffmann O., Amling M. and Wagner E.F. (2005). Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J. Clin. Invest. 115, 664-672.
17. Durchdewald M., Guinea-Viniegra J., Haag D., Riehl A., Lichter P., Hahn M., Wagner E.F., Angel P. and Hess J. (2008). Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res. 68, 6877-6883.
18. Eferl R. and Wagner E.F. (2003). AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3, 859-868.
19. Eger A., Stockinger A., Park J., Langkopf E., Mikula M., Gotzmann J., Mikulits W., Beug H. and Foisner R. (2004). beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 23, 2672-2680.
20. Eger A., Stockinger A., Schaffhauser B., Beug H. and Foisner R. (2000). Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J. Cell Biol. 148, 173-188.
21. Ferrara P., Andermarcher E., Bossis G., Acquaviva C., Brockly F., Jariel-Encontre I. and Piechaczyk M. (2003). The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene 22, 1461-1474.
22. Fleischmann A., Hafezi F., Elliott C., Reme C.E., Ruther U. and Wagner E.F. (2000). Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev. 14, 2695-2700.
23. Fleischmann A., Hvalby O., Jensen V., Strekalova T., Zacher C., Layer L.E., Kvello A., Reschke M., Spanagel R., Sprengel R., Wagner E.F. and Gass P. (2003). Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J. Neurosci. 23, 9116-9122.
24. Fleischmann A., Jochum W., Eferl R., Witowsky J. and Wagner E.F. (2003). Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell 4, 477-482.
25. Franchi A., Calzolari A. and Zampi G. (1998). Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch. 432, 515-519.
26. Fu L., Patel M.S., Bradley A., Wagner E.F. and Karsenty G. (2005). The molecular clock mediates leptin-regulated bone formation. Cell 122, 803-815.
27. Gack S., Vallon R., Schaper J., Ruther U. and Angel P. (1994). Phenotypic alterations in fos-transgenic mice correlate with changes in Fos/Jun-dependent collagenase type I expression. Regulation of mouse metalloproteinases by carcinogens, tumor promoters, cAMP, and Fos oncoprotein. J. Biol. Chem. 269, 10363-10369.
28. Gajate C., Alonso M.T., Schimmang T. and Mollinedo F. (1996). C-Fos is not essential for apoptosis. Biochem. Biophys. Res. Commun. 218, 267-272.
29. Gamberi G., Benassi M.S., Bohling T., Ragazzini P., Molendini L., Sollazzo M.R., Pompetti F., Merli M., Magagnoli G., Balladelli A. and Picci P. (1998). C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55, 556-563.
30. Gerdes M.J., Myakishev M., Frost N.A., Rishi V., Moitra J., Acharya A., Levy M.R., Park S.W., Glick A., Yuspa S.H. and Vinson C. (2006). Activator protein-1 activity regulates epithelial tumor cell identity. Cancer Res. 66, 7578-7588.
31. Gonzalez J.M., Navarro-Puche A., Casar B., Crespo P. and Andres V. (2008). Fast regulation of AP-1 activity through interaction of lamin A/C, ERK1/2, and c-Fos at the nuclear envelope. J. Cell Biol. 183, 653-666.
32. Greenhalgh D.A., Quintanilla M.I., Orengo C.C., Barber J.L., Eckhardt J.N., Rothnagel J.A. and Roop D.R. (1993). Cooperation between vfos and v-rasHA induces autonomous papillomas in transgenic epidermis but not malignant conversion. Cancer Res. 53, 5071-5075.
33. Greenhalgh D.A., Rothnagel J.A., Wang X.J., Quintanilla M.I., Orengo C.C., Gagne T.A., Bundman D.S., Longley M.A., Fisher C. and Roop D.R. (1993). Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggest a role for fos in epidermal differentiation and neoplasia. Oncogene 8, 2145-2157.
34. Grigoriadis A.E., Schellander K., Wang Z.Q. and Wagner E.F. (1993). Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol. 122, 685-701.
35. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A. and Wagner E.F. (1994). c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448.
36. Hafezi F., Steinbach J.P., Marti A., Munz K., Wang Z.Q., Wagner E.F., Aguzzi A. and Reme C.E. (1997). The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo. Nat. Med. 3, 346-349.
37. Hao W., Wenzel A., Obin M.S., Chen C.K., Brill E., Krasnoperova N.V., Eversole-Cire P., Kleyner Y., Taylor A., Simon M.I., Grimm C., Reme C.E. and Lem J. (2002). Evidence for two apoptotic pathways in light-induced retinal degeneration. Nat. Genet. 32, 254-260.
38. Hess J., Angel P. and Schorpp-Kistner M. (2004). AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci. 117, 5965-5973.
39. Hess J., Porte D., Munz C. and Angel P. (2001). AP-1 and Cbfa/runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast-specific element 2/AP-1 composite element. J. Biol. Chem. 276, 20029-20038.
40. Hummerich L., Muller R., Hess J., Kokocinski F., Hahn M., Furstenberger G., Mauch C., Lichter P. and Angel P. (2006). Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene 25, 111-121.
41. Ivorra C., Kubicek M., Gonzalez J.M., Sanz-Gonzalez S.M., Alvarez- Barrientos A., O'Connor J.E., Burke B. and Andres V. (2006). A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C. Genes Dev. 20, 307-320.
42. Jain J., Nalefski E.A., McCaffrey P.G., Johnson R.S., Spiegelman B.M., Papaioannou V. and Rao A. (1994). Normal peripheral T-cell function in c-Fos-deficient mice. Mol. Cell Biol. 14, 1566-1574.
43. Jeanes A., Gottardi C.J. and Yap A.S. (2008). Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27, 6920-6929.
44. Jin S.P., Kim J.H., Kim M.A., Yang H.K., Lee H.E., Lee H.S. and Kim W.H. (2007). Prognostic significance of loss of c-fos protein in gastric carcinoma. Pathol. Oncol. Res. 13, 284-289.
45. Johnson R.S., Spiegelman B.M. and Papaioannou V. (1992). Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71, 577-586.
46. Karsenty G. (2003). The complexities of skeletal biology. Nature 423, 316-318.
47. Kassel O., Schneider S., Heilbock C., Litfin M., Gottlicher M. and Herrlich P. (2004). A nuclear isoform of the focal adhesion LIMdomain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. Genes Dev. 18, 2518-2528.
48. Kovacs K.J. (2008). Measurement of immediate-early gene activationc- fos and beyond. J. Neuroendocrinol. 20, 665-672.
49. Krishnan J., Chen J., Shin K.J., Hwang J.I., Han S.U., Lee G. and Choi S. (2008). Gene expression profiling of light-induced retinal degeneration in phototransduction gene knockout mice. Exp. Mol. Med. 40, 495-504.
50. Lee H.J., Palkovits M. and Young W.S. 3rd. (2006). miR-7b, a microRNA up-regulated in the hypothalamus after chronic hyperosmolar stimulation, inhibits Fos translation. Proc. Natl. Acad. Sci. USA 103, 15669-15674.
51. Lee Y.N., Tuckerman J., Nechushtan H., Schutz G., Razin E. and Angel P. (2004). c-Fos as a regulator of degranulation and cytokine production in FcepsilonRI-activated mast cells. J. Immunol. 173, 2571-2577.
52. Levin W.J., Press M.F., Gaynor R.B., Sukhatme V.P., Boone T.C., Reissmann P.T., Figlin R.A., Holmes E.C., Souza L.M. and Slamon D.J. (1995). Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 11, 1261-1269.
53. Liu G., Takano T., Matsuzuka F., Higashiyama T., Kuma K. and Amino N. (1999). Screening of specific changes in mRNAs in thyroid tumors by sequence specific differential display: decreased expression of c-fos mRNA in papillary carcinoma. Endocr. J. 46, 459-466.
54. Macian F., Garcia-Rodriguez C. and Rao A. (2000). Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J. 19, 4783-4795.
55. Macian F., Lopez-Rodriguez C. and Rao A. (2001). Partners in transcription: NFAT and AP-1. Oncogene 20, 2476-2489.
56. Mahner S., Baasch C., Schwarz J., Hein S., Wolber L., Janicke F. and Milde-Langosch K. (2008). C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br. J. Cancer 99, 1269-1275.
57. Martins G.A., Cimmino L., Liao J., Magnusdottir E. and Calame K. (2008). Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J. Exp. Med. 205, 1959-1965.
58. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., Bachler M.A., Amano H., Aburatani H., Ishikawa H. and Wagner E.F. (2004). Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279, 26475-26480.
59. Matsuo K., Owens J.M., Tonko M., Elliott C., Chambers T.J. and Wagner E.F. (2000). Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24, 184-187.
60. Matsuo N., Reijmers L. and Mayford M. (2008). Spine-type-specific recruitment of newly synthesized AMPA receptors with learning. Science 319, 1104-1107.
61. Meinhold-Heerlein I., Bauerschlag D., Hilpert F., Dimitrov P., Sapinoso L.M., Orlowska-Volk M., Bauknecht T., Park T.W., Jonat W., Jacobsen A., Sehouli J., Luttges J., Krajewski M., Krajewski S., Reed J.C., Arnold N. and Hampton G.M. (2005). Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24, 1053-1065.
62. Mejlvang J., Kriajevska M., Berditchevski F., Bronstein I., Lukanidin E.M., Pringle J.H., Mellon J.K. and Tulchinsky E.M. (2007). Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition. Exp. Cell Res. 313, 380-393.
63. Murphy L.O., Smith S., Chen R.H., Fingar D.C. and Blenis J. (2002). Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4, 556-564.
64. Murphy M., Greferath U., Nag N., Nithianantharajah J. and Wilson Y.M. (2004). Tracing functional circuits using c-Fos regulated expression of marker genes targeted to neuronal projections. Front. Biosci. 9, 40-47.
65. O'Donnell A., Yang S.H. and Sharrocks A.D. (2008). MAP kinasemediated c-fos regulation relies on a histone acetylation relay switch. Mol. Cell 29, 780-785.
66. Okada S., Wang Z.Q., Grigoriadis A.E., Wagner E.F. and von Ruden T. (1994). Mice lacking c-fos have normal hematopoietic stem cells but exhibit altered B-cell differentiation due to an impaired bone marrow environment. Mol. Cell Biol. 14, 382-390.
67. Ozanne B.W., Spence H.J., McGarry L.C. and Hennigan R.F. (2007). Transcription factors control invasion: AP-1 the first among equals. Oncogene 26, 1-10.
68. Papachristou D.J., Batistatou A., Sykiotis G.P., Varakis I. and Papavassiliou A.G. (2003). Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone 32, 364-371.
69. Papavassiliou A.G., Treier M., Chavrier C. and Bohmann D. (1992). Targeted degradation of c-Fos, but not v-Fos, by a phosphorylationdependent signal on c-Jun. Science 258, 1941-1944.
70. Paylor R., Johnson R.S., Papaioannou V., Spiegelman B.M. and Wehner J.M. (1994). Behavioral assessment of c-fos mutant mice. Brain. Res. 651, 275-282.
71. Prusty B.K. and Das B.C. (2005). Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer 113, 951-960.
72. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J.S., Wagner E.F. and Schett G. (2002). Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest. 110, 1419-1427.
73. Reichmann E., Schwarz H., Deiner E.M., Leitner I., Eilers M., Berger J., Busslinger M. and Beug H. (1992). Activation of an inducible c- FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell 71, 1103-1116.
74. Reijmers L.G., Perkins B.L., Matsuo N. and Mayford M. (2007). Localization of a stable neural correlate of associative memory. Science 317, 1230-1233.
75. Robertson L.M., Kerppola T.K., Vendrell M., Luk D., Smeyne R.J., Bocchiaro C., Morgan J.I. and Curran T. (1995). Regulation of c-fos expression in transgenic mice requires multiple interdependent transcription control elements. Neuron 14, 241-252.
76. Ruther U., Garber C., Komitowski D., Muller R. and Wagner E.F. (1987). Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 325, 412-416.
77. Ruther U., Komitowski D., Schubert F.R. and Wagner E.F. (1989). c-fos expression induces bone tumors in transgenic mice. Oncogene 4, 861-865.
78. Saez E., Rutberg S.E., Mueller E., Oppenheim H., Smoluk J., Yuspa S. H. and Spiegelman B.M. (1995). c-fos is required for malignant progression of skin tumors. Cell 82, 721-732.
79. Sagar S.M., Sharp F.R. and Curran T. (1988). Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240, 1328-1331.
80. Sasaki T., Kojima H., Kishimoto R., Ikeda A., Kunimoto H. and Nakajima K. (2006). Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role. Mol. Cell 24, 63-75.
81. Scott D.L. and Kingsley G.H. (2006). Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355, 704-712.
82. Scott L.A., Vass J.K., Parkinson E.K., Gillespie D.A., Winnie J.N. and Ozanne B.W. (2004). Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation, immortalization, and the tumor suppressors p16INK4a and p53. Mol. Cell Biol. 24, 1540-1559.
83. Shaulian E. and Karin M. (2002). AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4, E131-136.
84. Shaw P.E. and Saxton J. (2003). Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. Int. J. Biochem. Cell Biol. 35, 1210-1226.
85. Sheng M. and Greenberg M.E. (1990). The regulation and function of cfos and other immediate early genes in the nervous system. Neuron 4, 477-485.
86. Shiozawa S., Shimizu K., Tanaka K. and Hino K. (1997). Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J. Clin. Invest. 99, 1210-1216.
87. Shiozawa S., Tanaka Y., Fujita T. and Tokuhisa T. (1992). Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice. J. Immunol. 148, 3100-3104.
88. Sibilia M., Fleischmann A., Behrens A., Stingl L., Carroll J., Watt F.M., Schlessinger J. and Wagner E.F. (2000). The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 102, 211-220.
89. Smeyne R.J., Schilling K., Robertson L., Luk D., Oberdick J., Curran T. and Morgan J.I. (1992). fos-lacZ transgenic mice: mapping sites of gene induction in the central nervous system. Neuron 8, 13-23.
90. Sunters A., McCluskey J. and Grigoriadis A.E. (1998). Control of cell cycle gene expression in bone development and during c-Fosinduced osteosarcoma formation. Dev. Genet. 22, 386-397.
91. Sunters A., Thomas D.P., Yeudall W.A. and Grigoriadis A.E. (2004). Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: induction of cyclin A and enhanced CDK2 activity. J. Biol. Chem. 279, 9882-9891.
92. Takahashi N., Udagawa N. and Suda T. (1999). A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256, 449-455.
93. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E.F., Mak T.W., Kodama T. and Taniguchi T. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901.
94. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., Yokochi T., Oda H., Nakamura K., Ida N., Wagner E.F. and Taniguchi T. (2002). RANKL maintains bone homeostasis through c- Fos-dependent induction of interferon-beta. Nature 416, 744-749.
95. Thiery J.P. and Sleeman J.P. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131-142.
96. Tischmeyer W. and Grimm R. (1999). Activation of immediate early genes and memory formation. Cell Mol. Life Sci. 55, 564-574.
97. Treisman R. (1995). Journey to the surface of the cell: Fos regulation and the SRE. EMBO J. 14, 4905-4913.
98. Tsuda H., Birrer M.J., Ito Y.M., Ohashi Y., Lin M., Lee C., Wong W.H., Rao P.H., Lau C.C., Berkowitz R.S., Wong K.K. and Mok S.C. (2004). Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet. Cytogenet. 155, 97-107.
99. Uhlirova M. and Bohmann D. (2006). JNK- and Fos-regulated Mmp1 expression cooperates with Ras to induce invasive tumors in Drosophila. EMBO J. 25, 5294-5304.
100. Van Beveren C., van Straaten F., Curran T., Muller R. and Verma I.M. (1983). Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell 32, 1241-1255.
101. Volm M., Drings P. and Wodrich W. (1993). Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J. Cancer Res. Clin. Oncol. 119, 507-510.
102. Wagner E.F. (2001). AP-1 reviews. Oncogene 20, 2333-2497.
103. Wagner E.F. and Eferl R. (2005). Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 208, 126-140.
104. Wagner E.F. and Matsuo K. (2003). Signalling in osteoclasts and the role of Fos/AP1 proteins. Ann. Rheum. Dis. 62 Suppl 2, ii83-85.
105. Wang X., Xiao G., Zhang Y., Wen X., Gao X., Okada S. and Liu X. (2008). Regulation of Tcrb recombination ordering by c-Fosdependent RAG deposition. Nat. Immunol. 9, 794-801.
106. Wang X.J., Greenhalgh D.A., Donehower L.A. and Roop D.R. (2000). Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. Mol. Carcinog. 29, 67-75.
107. Wang X.J., Greenhalgh D.A., Lu X.R., Bickenbach J.R. and Roop D.R. (1995). TGF alpha and v-fos cooperation in transgenic mouse epidermis induces aberrant keratinocyte differentiation and stable, autonomous papillomas. Oncogene 10, 279-289.
108. Wang Z.Q., Grigoriadis A.E., Mohle-Steinlein U. and Wagner E.F. (1991). A novel target cell for c-fos-induced oncogenesis: development of chondrogenic tumours in embryonic stem cell chimeras. EMBO J. 10, 2437-2450.
109. Wang Z.Q., Liang J., Schellander K., Wagner E.F. and Grigoriadis A.E. (1995). c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 55, 6244-6251.
110. Wang Z.Q., Ovitt C., Grigoriadis A.E., Mohle-Steinlein U., Ruther U. and Wagner E.F. (1992). Bone and haematopoietic defects in mice lacking c-fos. Nature 360, 741-745.
111. Welsh J.B., Zarrinkar P.P., Sapinoso L.M., Kern S.G., Behling C.A., Monk B.J., Lockhart D.J., Burger R.A. and Hampton G.M. (2001). Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 98, 1176-1181.
112. Wicki A. and Christofori G. (2007). The potential role of podoplanin in tumour invasion. Br. J. Cancer 96, 1-5.
113. Wicki A., Lehembre F., Wick N., Hantusch B., Kerjaschki D. and Christofori G. (2006). Tumor invasion in the absence of epithelialmesenchymal ransition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9, 261-272.
114. Yao D., Alexander C.L., Quinn J.A., Chan W.C., Wu H. and Greenhalgh D.A. (2008). Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity. J. Cell Sci. 121, 1758-1769.
115. Yasoshima Y., Sako N., Senba E. and Yamamoto T. (2006). Acute suppression, but not chronic genetic deficiency, of c-fos gene expression impairs long-term memory in aversive taste learning. Proc. Natl. Acad. Sci. USA 103, 7106-7111.
116. Young M.R., Li J.J., Rincon M., Flavell R.A., Sathyanarayana B.K., Hunziker R. and Colburn N. (1999). Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc. Natl. Acad. Sci. USA 96, 9827-9832.
117. Yuen M.F., Wu P.C., Lai V.C., Lau J.Y. and Lai C.L. (2001). Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 91, 106-112.
118. Zenz R., Eferl R., Scheinecker C., Redlich K., Smolen J., Schonthaler H.B., Kenner L., Tschachler E. and Wagner E.F. (2008). Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res. Ther. 10, 201.
119. Zhang J., McQuade J.M., Vorhees C.V. and Xu M. (2002a). Hippocampal expression of c-fos is not essential for spatial learning. Synapse 46, 91-99.
120. Zhang J., Zhang D., McQuade J.S., Behbehani M., Tsien J.Z. and Xu M. (2002b). c-fos regulates neuronal excitability and survival. Nat. Genet. 30, 416-420.